Want to see RZLT full AI Analyst Report?
Top Page
Rezolute
(NASDAQ:RZLT)
Select Model
Select Model
Rating:51Neutral
Price Target:
$4.00
▼(-20.16% Downside)
Action:Reiterated
Date:10/30/26
The score is held back primarily by weak financial performance (no revenue, widening losses, and heavy ongoing cash burn), partly offset by a low-debt balance sheet. Technicals are broadly neutral without clear momentum, while valuation is challenged by negative earnings and no dividend support. Corporate events add a modest positive tilt due to pre-BLA progress and late-stage program milestones, tempered by prior Phase 3 endpoint misses.
Positive Factors
Low Leverage and Financial Flexibility
A debt-free balance sheet and sizable equity base provide financial flexibility while Rezolute advances costly clinical programs. This reduces near-term solvency pressure and preserves capacity to fund development and regulatory activities without the immediate burden of substantial interest or refinancing obligations.
Negative Factors
Pre-Revenue Business Model
The absence of revenue leaves Rezolute dependent on financing and clinical progress rather than internally generated commercial cash flow. Until a candidate is approved and launched, the company has limited operating leverage and remains exposed to development setbacks that can delay any transition toward sustainable revenue.
Read all positive and negative factors
Positive Factors
Negative Factors
Low Leverage and Financial Flexibility
A debt-free balance sheet and sizable equity base provide financial flexibility while Rezolute advances costly clinical programs. This reduces near-term solvency pressure and preserves capacity to fund development and regulatory activities without the immediate burden of substantial interest or refinancing obligations.
Read all positive factors
Rezolute (RZLT) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$398.52M
Dividend YieldN/A
Average Volume (3M)1.76M
Price to Earnings (P/E)―
Beta (1Y)1.28
Revenue GrowthN/A
EPS Growth23.34%
CountryUS
Employees58
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.76
Shares Outstanding96,728,910
10 Day Avg. Volume1,464,307
30 Day Avg. Volume1,757,351
Financial Highlights & Ratios
PEG Ratio0.30
Price to Book (P/B)5.37
Price to Sales (P/S)0.00
P/FCF Ratio-8.36
Enterprise Value/Market Cap1.10
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-14.08K
Enterprise Value/Ebitda-5.55
Forecast
1Y Price Target
$10.00Price Target Upside99.60% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)-0.7
Revenue Forecast (FY)$2.88M
Rezolute Business Overview & Revenue Model
Company Description
Rezolute, Inc., a late-stage rare disease company, focused on improving outcomes for individuals with hypoglycemia caused by hyperinsulinism in the United States. Its lead clinical asset is ersodetug, an intravenously administered human monoclonal...
Rezolute Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
63
Positive
Cash Flow
24
Negative
| Breakdown | Jun 2026 | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -31.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -82.97M | -74.38M | -68.42M | -51.76M | -39.24M |
| Net Income | -77.59M | -74.41M | -68.46M | -51.79M | -41.06M |
Balance Sheet | |||||
| Total Assets | 112.85M | 175.49M | 132.74M | 123.72M | 152.42M |
| Cash, Cash Equivalents and Short-Term Investments | 107.80M | 167.86M | 126.87M | 101.90M | 150.41M |
| Total Debt | 934.00K | 1.61M | 2.23M | 2.48M | 188.00K |
| Total Liabilities | 12.16M | 13.36M | 11.73M | 7.55M | 2.95M |
| Stockholders Equity | 100.69M | 162.13M | 121.00M | 116.17M | 149.47M |
Cash Flow | |||||
| Free Cash Flow | -64.64M | -69.08M | -57.37M | -44.63M | -39.62M |
| Operating Cash Flow | -64.64M | -69.08M | -57.37M | -44.48M | -39.62M |
| Investing Cash Flow | -21.10M | -14.54M | 48.70M | -101.46M | 0.00 |
| Financing Cash Flow | 2.24M | 107.33M | 63.03M | 11.57M | 148.98M |
Rezolute Technical Analysis
Neutral
5.01
Price Trends
4.27
Negative
4.51
Negative
3.88
Positive
Market Momentum
-0.07
Negative
50.34
Neutral
84.33
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For RZLT, the sentiment is Neutral. The current price of 5.01 is above the 20-day moving average (MA) of 4.14, above the 50-day MA of 4.27, and above the 200-day MA of 3.88, indicating a neutral trend. The MACD of -0.07 indicates Negative momentum. The RSI at 50.34 is Neutral, neither overbought nor oversold. The STOCH value of 84.33 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for RZLT.
Rezolute Risk Analysis
Rezolute disclosed 31 risk factors in its most recent earnings report. Rezolute reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Rezolute Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
62 Neutral | $847.89M | 5.41 | 90.98% | ― | 1078.78% | ― | |
52 Neutral | $2.17B | -13.46 | -28.66% | ― | -28.56% | 10.25% | |
52 Neutral | $6.31B | -23.96 | -273.23% | ― | ― | -10.60% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $398.52M | -5.42 | -62.99% | ― | ― | 23.34% | |
50 Neutral | $1.38B | -9.99 | -56.19% | ― | -32.27% | -21.09% | |
46 Neutral | $607.91M | -9.49 | -30.31% | ― | 24.39% | 21.06% |
* Healthcare Sector Average
RZLT
Rezolute
4.12
-5.70
-58.04%
GERN
Geron
0.95
-0.29
-23.71%
ABUS
Arbutus Biopharma
4.28
-0.56
-11.57%
XNCR
Xencor
29.21
15.08
106.72%
KOD
Kodiak Sciences
100.40
79.35
376.96%
TSHA
Taysha Gene Therapies
4.22
-0.69
-14.05%
Rezolute Corporate Events
Business Operations and StrategyFinancial DisclosuresRegulatory Filings and Compliance
Rezolute Updates Investors on Lead Hyperinsulinism Therapy Progress
Positive
Oct 29, 2026
On October 29, 2026, Rezolute released an updated investor presentation outlining progress and plans for its lead antibody therapy ersodetug in treating refractory hypoglycemia linked to hyperinsulinism. The materials highlight that the company is...
Business Operations and StrategyProduct-Related Announcements
Rezolute Completes Phase 3 Enrollment for ersodetug
Positive
Oct 14, 2026
On October 14, 2026, Rezolute announced that enrollment has been completed in its Phase 3 upLIFT study of ersodetug in tumor hyperinsulinism, a registrational, single-arm, open-label trial in 16 participants with insulinoma or non-islet cell tumor...
Business Operations and StrategyRegulatory Filings and Compliance
Rezolute Advances Pre-BLA Strategy for Ersodetug Program
Positive
Oct 5, 2026
On October 5, 2026, Rezolute said the U.S. Food and Drug Administration recommended a Type B pre-BLA meeting as a precursor to a potential biologics license application for ersodetug in congenital hyperinsulinism, after reviewing detailed data fro...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.